| Literature DB >> 28666465 |
Woo-Kyoung Shin1, Sihan Song2, So-Youn Jung3, Eunsook Lee3, Zisun Kim4, Hyeong-Gon Moon5, Dong-Young Noh5, Jung Eun Lee6,7.
Abstract
BACKGROUND: The quality of life for breast cancer survivors has become increasingly important because of their high survival rate and prolonged life expectancy. The purpose of this study was to examine the association of physical activity following diagnosis and health-related quality of life (HRQOL) in breast cancer survivors.Entities:
Keywords: Breast cancer survivor; Health related quality of life; Korean women; Physical activity
Mesh:
Year: 2017 PMID: 28666465 PMCID: PMC5493872 DOI: 10.1186/s12955-017-0706-9
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Characteristics of study participants according to physical activity levels
| Physical Activity (MET-hours per week) | |||||
|---|---|---|---|---|---|
| All ( | Tertile 1 ( | Tertile 2 ( | Tertile 3 ( | P valuea) | |
| Physical activity (METs-hour per week)b | 33.66 (29.86) | 7.19 (5.29) | 26.96 (6.43) | 66.83 (27.56) | <0.001 |
| Age (year)b | 48.07 (8.36) | 46.94 (7.91) | 49.16 (8.89) | 48.12 (8.22) | 0.31 |
| Body Mass Index (kg/m2)b | 23.20 (3.13) | 23.62 (3.86) | 23.07 (2.97) | 22.92 (2.38) | 0.55 |
| Energy intake (kcal/day)b | 1778.30 (402.76) | 1693.07 (363.22) | 1805.71 (398.39) | 1825.96 (432.12) | 0.16 |
| Dietary supplement useb | |||||
| yes | 151 (65.37) | 48 (62.34) | 55 (71.43) | 48 (62.34) | 0.39 |
| no | 80 (34.63) | 29 (37.66) | 22 (28.57) | 29 (37.66) | |
| Time since surgeryb | |||||
| 6 month - 1 year | 32 (13.85) | 12 (15.58) | 8 (10.39) | 12 (15.58) | 0.70 |
| 1 year - 5 years | 172 (74.46) | 58 (75.32) | 60 (77.92) | 54 (70.13) | |
| 5 years ≤ | 27 (11.69) | 7 (9.09) | 9 (11.69) | 11 (14.29) | |
| AJCC stageb | |||||
| I | 101 (43.72) | 32 (41.56) | 36 (46.75) | 33 (42.86) | 0.90 |
| II | 108 (46.75) | 38 (49.35) | 35 (45.45) | 35 (45.45) | |
| III | 22 (9.52) | 7 (9.09) | 6 (7.79) | 9 (11.69) | |
| Menopausal status at the diagnosisb | |||||
| Postmenopause | 149 (64.50) | 53 (68.83) | 51 (66.23) | 45 (58.44) | 0.37 |
| Premenopause | 82 (35.50) | 24 (31.17) | 26 (33.77) | 32 (41.56) | |
| Alcohol intakeb | |||||
| Never drinker | 112 (48.70) | 36 (46.75) | 42 (54.55) | 34 (44.74) | 0.44 |
| Ever drinker | 118 (51.30) | 41 (53.25) | 35 (45.45) | 42 (55.26) | |
| Education levelb | |||||
| High school or less | 126 (55.26) | 38 (49.35) | 41 (53.95) | 47 (62.67) | 0.25 |
| College or more | 102 (44.74) | 39 (50.65) | 35 (46.05) | 28 (37.33) | |
| Marital statusb | |||||
| Married or cohabitation | 188 (81.74) | 58 (76.32) | 61 (79.22) | 69 (89.61) | 0.08 |
| Unmarried or divorced or widowed | 42 (18.26) | 18 (23.68) | 16 (20.78) | 8 (10.39) | |
MET metabolic equivalent, AJCC American Joint Committee on Cancer
aAnalysis of variance was used for continuous variables and chi-square test was used for categorical variables
bContinuous variables are reported as Mean value (sd) and Categorical variables are reported as No. (%)
Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors with stage I to III breast cancer
| HRQOL Items | Physical Activity (MET-hours per week) | ||||
|---|---|---|---|---|---|
| All | Tertile 1 | Tertile 2 | Tertile 3 | P for trenda | |
| EORTC QLQ-C30, LS means (95% CI)b | |||||
| Global health status / QoL | 206 | 45.25 (33.62, 60.90) | 31.99 (23.14, 44.22) | 40.10 (29.17, 55.12) | 0.64 |
| Functioning | |||||
| Physical Functioning | 229 | 78.44 (70.20, 87.65) | 81.12 (71.93, 91.48) | 82.53 (73.21, 93.05) | 0.41 |
| Role Functioning | 230 | 75.68 (59.77, 95.82) | 83.78 (64.68, 108.51) | 90.10 (69.98, 116.01) | 0.18 |
| Emotional Functioning | 231 | 75.16 (62.37, 90.58) | 72.87 (59.47, 89.31) | 75.67 (61.95, 92.44) | 0.89 |
| Cognitive Functioning | 231 | 75.13 (63.80, 88.47) | 72.40 (60.60, 86.51) | 71.47 (59.98, 85.16) | 0.59 |
| Social Functioning | 231 | 56.74 (44.62, 72.15) | 73.08 (56.25, 94.94) | 72.96 (56.39, 94.39) | 0.08 |
| Symptom | |||||
| Fatigue | 230 | 21.63 (16.07, 29.11) | 21.00 (15.20, 29.02) | 13.30 (9.64, 18.36) | 0.001 |
| Nausea / Vomiting | 231 | 2.56 (1.60, 4.09) | 2.33 (1.40, 3.89) | 2.54 (1.53, 4.20) | 0.97 |
| Pain | 230 | 12.45 (7.44, 20.83) | 7.90 (4.51, 13.83) | 6.25 (3.58, 10.93) | 0.02 |
| Dyspnea | 228 | 5.83 (3.38, 10.03) | 3.23 (1.79, 5.85) | 4.07 (2.25, 7.37) | 0.35 |
| Insomnia | 229 | 12.60 (7.38, 21.53) | 15.79 (8.81, 28.29) | 16.22 (9.07, 29.00) | 0.42 |
| Appetite loss | 228 | 2.22 (1.33, 3.70) | 2.69 (1.54, 4.69) | 2.10 (1.21, 3.65) | 0.72 |
| Constipation | 229 | 3.69 (2.09, 6.52) | 4.36 (2.35, 8.09) | 3.62 (1.95, 6.69) | 0.86 |
| Diarrhea | 231 | 2.95 (1.77, 4.91) | 2.26 (1.30, 3.95) | 2.35 (1.36, 4.07) | 0.48 |
| Financial Problems | 231 | 4.46 (2.56, 7.77) | 5.96 (3.26, 10.90) | 3.29 (1.81, 5.95) | 0.19 |
| EORTC QLQ-BR23, LS means (95% CI)b | |||||
| Functioning | |||||
| Body image | 231 | 36.03 (24.05, 54.00) | 34.95 (22.49, 54.30) | 32.14 (20.83, 49.58) | 0.58 |
| Sexual functioning | 209 | 2.69 (1.53, 4.71) | 2.57 (1.43, 4.65) | 5.34 (3.04, 9.39) | 0.007 |
| Sexual enjoyment | 69 | 16.89 (4.80, 59.47) | 9.65 (3.14, 29.62) | 11.54 (3.34, 39.90) | 0.56 |
| Future perspective | 231 | 17.83 (10.65, 29.83) | 18.04 (10.29, 31.60) | 19.72 (11.35, 34.24) | 0.70 |
| Symptom | |||||
| Systematic therapy side effects | 231 | 21.59 (16.54, 28.19) | 23.55 (17.62, 31.49) | 19.06 (14.32, 25.36) | 0.29 |
| Breast symptoms | 231 | 12.45 (8.04, 19.28) | 10.06 (6.25, 16.20) | 10.42 (6.52, 16.65) | 0.52 |
| Arm symptoms | 231 | 18.20 (12.41, 26.69) | 21.04 (13.86, 31.93) | 17.92 (11.89, 27.02) | 0.83 |
| Upset by hair loss | 157 | 17.28 (8.92, 33.50) | 14.78 (7.09, 30.83) | 17.59 (8.60, 36.00) | 0.90 |
MET metabolic equivalent, EORTC QLQ-C30 European organization for research and treatment of cancer quality of life questionnaire core 30, LS least-squares, CI confidence interval, EORTC QLQ-BR23 European organization for research and treatment of cancer quality of life questionnaire breast cancer module 23
aP for trend was calculated using the median value of each tertile category as a continuous variable
bAdjusted for age (year: continuous), energy intake (kcal/day: continuous), dietary supplement use (yes, no), education level (high school or less, college or more), marital status (married or cohabitated, unmarried or divorced or widowed), time since surgery (6 month – 1 year, 1 year - 5 years, ≥5 years), stage (I, II, or III), and center
Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors with stage I breast cancer
| HRQOL Items | Physical Activity (MET-hours per week) | ||||
|---|---|---|---|---|---|
| All | Tertile 1 | Tertile 2 | Tertile 3 | P for trenda | |
| EORTC QLQ-C30, LS means (95% CI)b | |||||
| Global health status / QoL | 93 | 44.40 (27.04, 72.90) | 33.27 (20.51, 53.98) | 34.72 (20.75, 58.08) | 0.35 |
| Functioning | |||||
| Physical Functioning | 101 | 74.97 (67.56, 83.20) | 76.85 (69.59, 84.87) | 84.62 (76.17, 94.00) | 0.01 |
| Role Functioning | 101 | 79.69 (60.00, 105.84) | 71.11 (54.25, 93.20) | 88.10 (66.14, 117.35) | 0.36 |
| Emotional Functioning | 101 | 83.73 (57.88, 121.12) | 79.85 (56.16, 113.54) | 80.11 (55.17, 116.33) | 0.83 |
| Cognitive Functioning | 101 | 77.91 (65.43, 92.78) | 77.49 (65.61, 91.52) | 67.46 (56.55, 80.48) | 0.07 |
| Social Functioning | 101 | 57.30 (39.62, 82.86) | 70.40 (49.53, 100.07) | 76.72 (52.85, 111.36) | 0.12 |
| Symptom | |||||
| Fatigue | 101 | 27.95 (17.23, 45.34) | 25.32 (15.97, 40.16) | 16.29 (9.99, 26.55) | 0.02 |
| Nausea / Vomiting | 101 | 2.56 (1.15, 5.70) | 2.75 (1.28, 5.89) | 3.06 (1.37, 6.87) | 0.64 |
| Pain | 101 | 11.16 (4.92, 25.29) | 7.64 (3.50, 16.65) | 5.92 (2.59, 13.52) | 0.12 |
| Dyspnea | 99 | 5.25 (2.13, 12.96) | 3.46 (1.46, 8.21) | 4.02 (1.60, 10.13) | 0.63 |
| Insomnia | 101 | 14.61 (6.19, 34.49) | 14.90 (6.57, 33.78) | 22.14 (9.30, 52.72) | 0.29 |
| Appetite loss | 100 | 1.35 (0.54, 3.38) | 2.04 (0.86, 4.84) | 1.57 (0.63, 3.91) | 0.85 |
| Constipation | 101 | 3.70 (1.42, 9.67) | 6.01 (2.41, 15.02) | 8.35 (3.17, 22.04) | 0.09 |
| Diarrhea | 101 | 3.01 (1.36, 6.67) | 2.27 (1.06, 4.84) | 1.63 (0.73, 3.65) | 0.12 |
| Financial Problems | 101 | 2.82 (1.12, 7.07) | 3.20 (1.33, 7.69) | 1.92 (0.76, 4.86) | 0.33 |
| EORTC QLQ-BR23, LS means (95% CI)b | |||||
| Functioning | |||||
| Body image | 101 | 68.77 (39.53, 119.62) | 65.36 (38.56, 110.80) | 57.80 (33.04, 101.11) | 0.51 |
| Sexual functioning | 94 | 4.12 (1.54, 11.03) | 4.56 (1.80, 11.54) | 5.57 (2.12, 14.60) | 0.50 |
| Sexual enjoyment | 33 | 53.86 (7.89, 367.75) | 36.75 (7.85, 172.11) | 21.84 (3.57, 133.78) | 0.25 |
| Future perspective | 101 | 25.27 (10.25, 62.28) | 30.21 (12.79, 71.39) | 29.68 (11.93, 73.83) | 0.75 |
| Symptom | |||||
| Systematic therapy side effects | 101 | 16.48 (10.39, 26.14) | 15.77 (10.16, 24.48) | 12.99 (8.15, 20.70) | 0.27 |
| Breast symptoms | 101 | 5.94 (3.08, 11.44) | 6.82 (3.65, 12.74) | 5.27 (2.72, 10.22) | 0.63 |
| Arm symptoms | 101 | 13.47 (7.64, 23.77) | 13.75 (8.00, 23.62) | 11.58 (6.52, 20.54) | 0.55 |
| Upset by hair loss | 69 | 14.10 (4.83, 41.22) | 7.35 (2.41, 22.41) | 15.16 (4.30, 53.40) | 0.80 |
MET metabolic equivalent, EORTC QLQ-C30 European organization for research and treatment of cancer quality of life questionnaire core 30, LS least-squares, CI confidence interval, EORTC QLQ-BR23 European organization for research and treatment of cancer quality of life questionnaire Breast cancer module 23
aP for trend was calculated using the median value of each tertile category as a continuous variable
bAdjusted for age (year: continuous), energy intake (kcal/day: continuous), dietary supplement use (yes, no), education level (high school or less, college or more), marital status (married or cohabitated, unmarried or divorced or widowed), time since surgery (6 month – 1 year, 1 year - 5 years, ≥5 years), and center
Health-related quality of life (HRQOL) scores according to physical activity levels among breast cancer survivors with stage II and III breast cancer
| HRQOL Items | Physical Activity (MET-hours per week) | ||||
|---|---|---|---|---|---|
| All | Tertile 1 | Tertile 2 | Tertile 3 | P for trenda | |
| EORTC QLQ-C30, LS means (95% CI)b | |||||
| Global health status / QoL | 113 | 48.33 (32.27, 72.39) | 31.37 (19.83, 49.61) | 43.56 (28.54, 66.49) | 0.89 |
| Functioning | |||||
| Physical Functioning | 128 | 81.46 (68.05, 97.51) | 85.19 (69.31, 104.72) | 81.99 (67.23, 99.98) | 0.98 |
| Role Functioning | 129 | 76.34 (53.02, 109.91) | 100.65 (65.83, 153.89) | 95.71 (64.41, 142.23) | 0.36 |
| Emotional Functioning | 130 | 72.94 (59.76, 89.03) | 67.19 (53.42, 84.51) | 75.44 (60.73, 93.71) | 0.63 |
| Cognitive Functioning | 130 | 77.05 (59.64, 99.56) | 69.47 (51.73, 93.29) | 75.00 (56.74, 99.13) | 0.96 |
| Social Functioning | 130 | 59.44 (42.46, 83.22) | 78.02 (52.98, 114.91) | 70.92 (49.17, 102.29) | 0.49 |
| Symptom | |||||
| Fatigue | 129 | 18.19 (12.29, 26.91) | 19.25 (12.25, 30.25) | 11.47 (7.43, 17.71) | 0.02 |
| Nausea / Vomiting | 130 | 2.53 (1.38, 4.63) | 2.20 (1.09, 4.41) | 2.17 (1.12, 4.19) | 0.69 |
| Pain | 129 | 11.40 (5.74, 22.67) | 7.32 (3.32, 16.17) | 6.15 (2.87, 13.17) | 0.14 |
| Dyspnea | 129 | 5.29 (2.60, 10.74) | 2.90 (1.28, 6.57) | 3.93 (1.79, 8.61) | 0.63 |
| Insomnia | 128 | 12.16 (6.05, 24.45) | 19.57 (8.75, 43.75) | 12.05 (5.56, 26.12) | 0.78 |
| Appetite loss | 128 | 2.28 (1.25, 4.15) | 3.06 (1.53, 6.09) | 2.11 (1.09, 4.10) | 0.67 |
| Constipation | 128 | 3.90 (1.87, 8.15) | 3.56 (1.53, 8.27) | 1.93 (0.86, 4.34) | 0.08 |
| Diarrhea | 130 | 2.72 (1.36, 5.45) | 2.11 (0.95, 4.69) | 3.51 (1.65, 7.46) | 0.40 |
| Financial Problems | 130 | 5.33 (2.56, 11.10) | 8.65 (3.72, 20.11) | 4.30 (1.94, 9.56) | 0.42 |
| EORTC QLQ-BR23, LS means (95% CI)b | |||||
| Functioning | |||||
| Body image | 130 | 26.17 (14.74, 46.48) | 24.74 (12.78, 47.91) | 22.67 (12.13, 42.35) | 0.66 |
| Sexual functioning | 115 | 1.97 (1.00, 3.85) | 1.61 (0.76, 3.41) | 5.77 (2.92, 11.39) | 0.001 |
| Sexual enjoyment | 36 | 10.24 (1.60, 65.60) | 3.36 (0.64, 17.61) | 7.46 (1.29, 43.12) | 0.97 |
| Future perspective | 130 | 16.23 (8.49, 31.02) | 12.63 (5.99, 26.62) | 15.43 (7.62, 31.23) | >0.99 |
| Symptom | |||||
| Systematic therapy side effects | 130 | 23.04 (16.92, 31.36) | 30.31 (21.25, 43.22) | 23.11 (16.52, 32.33) | 0.75 |
| Breast symptoms | 130 | 16.84 (9.26, 30.60) | 11.09 (5.58, 22.06) | 14.16 (7.39, 27.13) | 0.77 |
| Arm symptoms | 130 | 19.83 (11.69, 33.65) | 26.64 (14.50, 48.95) | 22.71 (12.77, 40.37) | 0.78 |
| Upset by hair loss | 88 | 19.92 (7.97, 49.81) | 26.82 (9.60, 74.98) | 22.28 (8.72, 56.92) | 0.89 |
MET metabolic equivalent, EORTC QLQ-C30 European organization for research and treatment of cancer quality of life questionnaire core 30, LS least-squares, CI confidence interval, EORTC QLQ-BR23 European organization for research and treatment of cancer quality of life questionnaire breast cancer module 23
aP for trend was calculated using the median value of each tertile category as a continuous variable
bAdjusted for age (year: continuous), energy intake (kcal/day: continuous), dietary supplement use (yes, no), education level (high school or less, college or more), marital status (married or cohabitated, unmarried or divorced or widowed), time since surgery (6 month – 1 year, 1 year - 5 years, ≥ 5 years), stage (II or III), and center